Cardiology In The Time of COVID-19: Cell Therapy to Modulate Inflammation
In response to the evolving pandemic, the Texas Heart Institute (THI) is dedicating its education series, Innovative Technologies & Techniques, to providing information to those in the medical community who are taking care of cardiovascular patients with and without COVID-19. The special series, Cardiology in the Time of COVID-19, will include discussions of current COVID-19 and cardiovascular care literature and will provide an online educational forum for discussing emerging topics related to preparing for and taking care of all patients being treated for COVID-19.
In each episode, THI medical directors and leadership interview experts in their respective fields to provide early perspectives on relevant topics. The initial topics of discussion explore strategies to consider when preparing facilities and staff for case surge and innovative practices for overcoming challenges to providing cardiac care during this unprecedented time. Importantly, because best practices are in flux and are evolving as we learn more about how this virus manifests, we will continually update and make available these web-based vignettes, for the educational benefit of our global medical community.
In this episode, the series hosts Drs. Zvonimir Krajcer, and Stephanie Coulter welcome special guest, Emerson Perin, MD, PhD, Texas Heart Institute’s Medical Director and Director of the Center for Clinical Research.
For more than two decades, Dr. Perin led has led multiple cell therapy clinical trials focusing on the treatment of heart failure, acute myocardial infarction, refractory angina, and peripheral arterial disease. In Cardiology In The Time of COVID-19: Cell Therapy to Modulate Inflammation, he discusses the potential role of cell therapy to modulate inflammation in patients with the coronavirus disease.